United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2013_register executive 2013-06-20 article Notices D09002ee1c7fb573c D09002ee1c7fb57b0 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant to Mitchell Woods Pharmaceuticals, LLC, of an exclusive commercialization license to practice the inventions embodied in the following U.S. Patent Applications (and all continuing applications and foreign counterparts): Serial No. 61/651,961, filed May 25, 2012, entitled, "Methods of Regulating Cannabinoid Receptor Activity-related Disorders and Diseases" [HHS Reference E-139-2012/0-US-1]; Serial No. 61/ 789,629, filed March 15, 2013, entitled, "Methods of Regulating Cannabinoid Receptor Activity-related Disorders and Diseases" [HHS Reference E-139-2012/1-US-1]; Serial No. 61/312,642, filed March 10, 2010, entitled, "The Use of Fenoterol and Fenoterol Analogues in the Treatment of Glioblastomas and Astrocytomas" [HHS Reference E-013- 2010/0-US-01]; Serial No. 60/837,161, filed August 10, 2006, entitled, "Preparation of R,R-Fenoterol and R,R-Fenoterol Analogues and Their Use in Congestive Heart Failure" [HHS Reference E-205-2006/0-US-1]; and Serial No. 60/927,825, filed May 3, 2007, entitled "Preparation of R,R-Fenoterol and R,R-Fenoterol Analogues and Their Use in Congestive Heart Failure" [HHS Reference E-205-2006/1-US-1]. The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America. The prospective exclusive commercialization license territory may be worldwide, and the scope may be limited to the following two fields of use: 78 FR 37234 https://www.govinfo.gov/app/details/FR-2013-06-20/2013-14645 2013-14645 fr20jn13-85 4140-01-P https://www.govinfo.gov/app/details/FR-2013-06-20/2013-14645 https://www.govinfo.gov/content/pkg/FR-2013-06-20/html/2013-14645.htm https://www.govinfo.gov/content/pkg/FR-2013-06-20/pdf/2013-14645.pdf 1 p. 37234 37234 78 FR 37234 Prospective Grant of Exclusive License: Start-Up Commercial License for the Development of Fenoterol and Fenoterol Analogues for the Treatment of Brain, Liver, and Pancreatic Cancers and Congestive Heart Failure; Federal Register Vol. 78, Issue NOTICE 2013-14645 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2013-07-05 4140-01-P 2013-14645 Notice.

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant to Mitchell Woods Pharmaceuticals, LLC, of an exclusive commercialization license to practice the inventions embodied in the following U.S. Patent Applications (and all continuing applications and foreign counterparts): Serial No. 61/651,961, filed May 25, 2012, entitled, "Methods of Regulating Cannabinoid Receptor Activity-related Disorders and Diseases" [HHS Reference E-139-2012/0-US-1]; Serial No. 61/ 789,629, filed March 15, 2013, entitled, "Methods of Regulating Cannabinoid Receptor Activity-related Disorders and Diseases" [HHS Reference E-139-2012/1-US-1]; Serial No. 61/312,642, filed March 10, 2010, entitled, "The Use of Fenoterol and Fenoterol Analogues in the Treatment of Glioblastomas and Astrocytomas" [HHS Reference E-013- 2010/0-US-01]; Serial No. 60/837,161, filed August 10, 2006, entitled, "Preparation of R,R-Fenoterol and R,R-Fenoterol Analogues and Their Use in Congestive Heart Failure" [HHS Reference E-205-2006/0-US-1]; and Serial No. 60/927,825, filed May 3, 2007, entitled "Preparation of R,R-Fenoterol and R,R-Fenoterol Analogues and Their Use in Congestive Heart Failure" [HHS Reference E-205-2006/1-US-1]. The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America. The prospective exclusive commercialization license territory may be worldwide, and the scope may be limited to the following two fields of use:

Only written comments or applications for a license (or both) which are received by the NIH Office of Technology Transfer on or before July 5, 2013 will be considered. Prospective Grants of Exclusive Licenses: Development of Fenoterol and Fenoterol Analogues, etc. , mccuepat@mail.nih.gov Vol. 78, no. 119 Office of the Federal Register, National Archives and Records Administration 2013-06-20 continuing daily deposited born digital 343 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2013-06-20 P0b002ee18501b9a8 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr20jn13 https://www.govinfo.gov/app/details/FR-2013-06-20 https://www.govinfo.gov/content/pkg/FR-2013-06-20/pdf/FR-2013-06-20.pdf https://www.govinfo.gov/content/pkg/FR-2013-06-20/xml/FR-2013-06-20.xml fdlp 37101 37435 DGPO 2013-06-20 2024-06-03 FR-2013-06-20 machine generated eng FR FR-2013-06-20 78 119